Embedded Files
Topics
Topics
December 22, 2025 CEO Toru Kawamura Participated in the Kinki Regional Round of “NIKKEI THE PITCH GROWTH”
December 8, 2025 CEO Toru Kawamura Featured on “the University of Karuizawa radio”
September 18, 2025 Our R&D Featured in the Media
September 18, 2025 Entered into a Joint Research Agreement with KANEKA CORPORATION
September 4, 2025 Selected for AMED’s "Strengthening Program for Pharmaceutical Startup Ecosystem" (9th Call)
July 31, 2025 Our Funding Featured in the Media
July 30, 2025 Series B Funding Round of JPY 850 Million Completed
June 1, 2025 Research Project with Our Participation as Co-Investigator Selected for the AMED FY2025 Translational Research Program (Seeds B)
2024
2024
June 6, 2024 Featured in Nikkei Biotechnology & Business Online
May 23, 2024 Founder Masahiro Shiokawa to Speak at an Online Event
April 1, 2024 Selected for AMED’s FY2023 AIMGAIN Program as a Startup Company
March 18, 2024 Interview Featured on the KYOTO-iCAP Website
2023
2023
October 25, 2023 Selected for the FY2023 KYOTO Industrial Support Organization 21 “Industry–Academia–Public Forest” Promotion Project
September 25, 2023 Founder Masahiro Shiokawa to Speak at BioJapan 2023
May 23, 2023 Research by Founder Masahiro Shiokawa Featured on NHK and in The Kyoto Shimbun
March 9, 2023 Announcement of Office Relocation
February 28, 2023 Completion of Third-Party Allotment of New Shares
January 21, 2023 Research by Founder Masahiro Shiokawa Featured on an Asahi Broadcasting Television Program
2022
2022
December 22, 2022 Seed Funding Round Completed
December 16, 2022 Entered into a License Agreement with Kyoto University for Anti-Integrin αVβ6 Antibody
October 4, 2022 Company founded
Report abuse